Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -721.75% is 1282% below its 5-year average of 61.09%, near the low end of its 5-year range (-721.75%–1050.35%).
As of the fiscal period ended Monday, March 31, 2025. 307.19% below its 12-month average of 348.35%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-721.75%
RETURN ON EQUITY (ROE) AVG TTM
348.35%
RETURN ON EQUITY (ROE) AVG 3Y
157.32%
RETURN ON EQUITY (ROE) AVG 5Y
61.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-307.19%
CURRENT VS 3Y AVG
-558.76%
CURRENT VS 5Y AVG
-1281.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-6727.64%
vs the sector median at left
23andMe Holding Co.
Market Cap
$15.31M
Return on Equity (ROE)
-721.75%
TTM Avg
348.35%
3Y Avg
157.32%
5Y Avg
61.09%
Market Cap
$439.69M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$471.59M
Return on Equity (ROE)
-33.14%
TTM Avg
-52.50%
3Y Avg
-47.15%
5Y Avg
-47.15%
Market Cap
$1.21B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$2.64B
Return on Equity (ROE)
34.80%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$2.68B
Return on Equity (ROE)
-47.65%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$6.19B
Return on Equity (ROE)
-2.97%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$7.69B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
Market Cap
$8.09B
Return on Equity (ROE)
-2.37%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| NRC Health (NRC)vs › | $439.69M | 89.43% | 81.07% | 67.39% | 61.90% |
| Shoulder Innovations, Inc. (SI)vs › | $471.59M | -33.14% | -52.50% | -47.15% | -47.15% |
| Teladoc Health, Inc. (TDOC)vs › | $1.21B | -13.54% | -40.81% | -170.75% | -114.78% |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 34.80% | 27.86% | 4.54% | -12.45% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.68B | -47.65% | -45.75% | -30.11% | -18.95% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.19B | -2.97% | 25.09% | 5.57% | 0.40% |
| Tempus AI, Inc. (TEM)vs › | $7.69B | -57.18% | -651.33% | -315.37% | -198.08% |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | -2.37% | -21.41% | -36.14% | -25.75% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.80B | 2.46% | -8.94% | -15.72% | 1.14% |
ROE
-721.8%
ROA
-163.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | 1050.35% |
| 2024-03-31 | -353.65% |
| 2023-03-31 | -43.65% |
| 2022-03-31 | -23.75% |
| 2021-03-31 | -75.85% |
| 2020-03-31 | -186.93% |
| 2019-03-31 | -58.49% |
